Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0P3SY
|
||||
| Former ID |
DAP001363
|
||||
| Drug Name |
Danaparoid
|
||||
| Synonyms |
Orgaran (TN)
|
||||
| Indication | Deep venous clots [ICD9: 453.4; ICD10:I80.2] | Approved | [1], [2] | ||
| Therapeutic Class |
Anticoagulants
|
||||
| Company |
Schering-Plough
|
||||
| CAS Number |
CAS 83513-48-8
|
||||
| Target and Pathway | |||||
| Target(s) | Coagulation factor Xa | Target Info | Inhibitor | [3] | |
| KEGG Pathway | Complement and coagulation cascades | ||||
| PANTHER Pathway | Blood coagulation | ||||
| Pathway Interaction Database | Beta2 integrin cell surface interactions | ||||
| PathWhiz Pathway | Coagulation | ||||
| Reactome | Extrinsic Pathway of Fibrin Clot Formation | ||||
| Intrinsic Pathway of Fibrin Clot Formation | |||||
| Common Pathway of Fibrin Clot Formation | |||||
| Gamma-carboxylation of protein precursors | |||||
| Transport of gamma-carboxylated protein precursors from the endoplasmic reticulum to the Golgi apparatus | |||||
| Removal of aminoterminal propeptides from gamma-carboxylated proteins | |||||
| WikiPathways | Complement and Coagulation Cascades | ||||
| Human Complement System | |||||
| PTM: gamma carboxylation, hypusine formation and arylsulfatase activation | |||||
| Blood Clotting Cascade | |||||
| Formation of Fibrin Clot (Clotting Cascade) | |||||
| References | |||||
| REF 1 | A comparison of danaparoid and lepirudin in heparin-induced thrombocytopenia. Thromb Haemost. 2001 Jun;85(6):950-7. | ||||
| REF 2 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6804). | ||||
| REF 3 | Effect of factor X inhibition on coagulation activation and cytokine induction in human systemic inflammation. J Infect Dis. 2002 Nov 1;186(9):1270-6. Epub 2002 Oct 8. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.